^
    2d
    A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Regeneron Pharmaceuticals | Trial completion date: Nov 2029 --> Dec 2030 | Initiation date: Mar 2025 --> Mar 2026 | Trial primary completion date: Apr 2027 --> Jun 2028
    Trial completion date • Trial initiation date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    3d
    Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P2 trial
    |
    capecitabine • oxaliplatin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    30d
    LAG-MAPS: Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma (clinicaltrials.gov)
    P2, N=126, Not yet recruiting, Intergroupe Francophone de Cancerologie Thoracique
    New P2 trial
    |
    cisplatin • carboplatin • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    1m
    A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery (clinicaltrials.gov)
    P2, N=180, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Apr 2029 --> Nov 2029 | Trial primary completion date: Sep 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    2ms
    LAG-BOOST: Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=72, Not yet recruiting, University of Oklahoma
    New P2 trial
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    3ms
    A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment (clinicaltrials.gov)
    P2, N=68, Not yet recruiting, University of Chicago
    New P2 trial • Minimal residual disease
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    4ms
    Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT) (clinicaltrials.gov)
    P2, N=36, Recruiting, Columbia University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • gemcitabine • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    4ms
    R5668-ONC-1938: A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab (clinicaltrials.gov)
    P1/2, N=612, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Apr 2027 --> Nov 2027
    Trial completion date
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767) • ubamatamab (REGN4018) • Kevzara (sarilumab) • REGN5668
    4ms
    Targeting LAG-3: Relatlimab, Fianlimab, and ieramilimab reshape the landscape of cancer combination immunotherapy. (PubMed, Pathol Res Pract)
    This review discusses the biology of LAG-3, the pharmacological characteristics of Relatlimab, Fianlimab, and Ieramilimab, as well as their potential synergistic effects when combined with other ICIs. Moreover, it addresses resistance mechanisms, patient selection, and challenges with combination therapies in cancer.
    Review • Journal
    |
    LAG3 (Lymphocyte Activating 3)
    |
    fianlimab (REGN3767) • relatlimab (BMS-986016) • ieramilimab (LAG525)
    5ms
    A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE) (clinicaltrials.gov)
    P2, N=79, Not yet recruiting, NSABP Foundation Inc
    New P2 trial • Minimal residual disease
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    6ms
    Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2, N=220, Recruiting, Regeneron Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Platinum resistant
    |
    Avastin (bevacizumab) • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767) • ubamatamab (REGN4018) • Kevzara (sarilumab)
    7ms
    LAG3 PET Imaging in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=41, Active, not recruiting, University Medical Center Groningen | Trial completion date: Sep 2024 --> Nov 2025 | Trial primary completion date: Sep 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)